nodes	percent_of_prediction	percent_of_DWPC	metapath
Masoprocol—CYP19A1—semen—cervical cancer	0.0914	0.122	CbGeAlD
Masoprocol—IGF1R—Irinotecan—Topotecan—cervical cancer	0.0636	1	CbGdCrCtD
Masoprocol—LTB4R—uterine cervix—cervical cancer	0.0548	0.0732	CbGeAlD
Masoprocol—LTB4R—mammalian vulva—cervical cancer	0.0479	0.0641	CbGeAlD
Masoprocol—IGF1R—epithelium—cervical cancer	0.0456	0.061	CbGeAlD
Masoprocol—IGF1R—renal system—cervical cancer	0.0423	0.0566	CbGeAlD
Masoprocol—LTB4R—female gonad—cervical cancer	0.0373	0.0499	CbGeAlD
Masoprocol—LTB4R—vagina—cervical cancer	0.0371	0.0496	CbGeAlD
Masoprocol—IGF1R—female reproductive system—cervical cancer	0.0339	0.0453	CbGeAlD
Masoprocol—IGF1R—female gonad—cervical cancer	0.0308	0.0412	CbGeAlD
Masoprocol—IGF1R—vagina—cervical cancer	0.0306	0.041	CbGeAlD
Masoprocol—CYP2J2—endometrium—cervical cancer	0.0277	0.0371	CbGeAlD
Masoprocol—CYP2J2—mammalian vulva—cervical cancer	0.0268	0.0359	CbGeAlD
Masoprocol—CYP2J2—uterus—cervical cancer	0.0255	0.0342	CbGeAlD
Masoprocol—LTB4R—lymph node—cervical cancer	0.024	0.0321	CbGeAlD
Masoprocol—ALOX5—decidua—cervical cancer	0.023	0.0308	CbGeAlD
Masoprocol—CYP2J2—female reproductive system—cervical cancer	0.023	0.0307	CbGeAlD
Masoprocol—CYP2J2—vagina—cervical cancer	0.0208	0.0278	CbGeAlD
Masoprocol—IGF1R—lymph node—cervical cancer	0.0198	0.0265	CbGeAlD
Masoprocol—ALOX5—female reproductive system—cervical cancer	0.0181	0.0242	CbGeAlD
Masoprocol—ALOX5—female gonad—cervical cancer	0.0165	0.022	CbGeAlD
Masoprocol—CYP2J2—Tryptophan metabolism—UBE3A—cervical cancer	0.0153	0.081	CbGpPWpGaD
Masoprocol—CYP19A1—endometrium—cervical cancer	0.0151	0.0202	CbGeAlD
Masoprocol—CYP19A1—uterus—cervical cancer	0.0139	0.0186	CbGeAlD
Masoprocol—CYP19A1—female reproductive system—cervical cancer	0.0125	0.0167	CbGeAlD
Masoprocol—CYP19A1—female gonad—cervical cancer	0.0114	0.0152	CbGeAlD
Masoprocol—ALOX5—lymph node—cervical cancer	0.0106	0.0142	CbGeAlD
Masoprocol—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—WNT5A—cervical cancer	0.0099	0.0524	CbGpPWpGaD
Masoprocol—CYP19A1—lymph node—cervical cancer	0.00732	0.00978	CbGeAlD
Masoprocol—CYP19A1—Tryptophan metabolism—UBE3A—cervical cancer	0.00702	0.0372	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00687	0.0364	CbGpPWpGaD
Masoprocol—IGF1R—Endochondral Ossification—FGFR3—cervical cancer	0.00569	0.0302	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—TAAR6—cervical cancer	0.00523	0.0277	CbGpPWpGaD
Masoprocol—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—CTNNB1—cervical cancer	0.00497	0.0264	CbGpPWpGaD
Masoprocol—IGF1R—Integrins in angiogenesis—CASP8—cervical cancer	0.00493	0.0261	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—CASP3—cervical cancer	0.00464	0.0246	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—CTNNB1—cervical cancer	0.00447	0.0237	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—FGFR3—cervical cancer	0.00437	0.0232	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—FGFR3—cervical cancer	0.00426	0.0226	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—WNT2—cervical cancer	0.00408	0.0216	CbGpPWpGaD
Masoprocol—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—EGFR—cervical cancer	0.00394	0.0209	CbGpPWpGaD
Masoprocol—IGF1R—Apoptosis—CASP8—cervical cancer	0.00392	0.0207	CbGpPWpGaD
Masoprocol—IGF1R—TSH signaling pathway—MTOR—cervical cancer	0.00391	0.0207	CbGpPWpGaD
Masoprocol—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—cervical cancer	0.00354	0.0188	CbGpPWpGaD
Masoprocol—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—MTOR—cervical cancer	0.00322	0.0171	CbGpPWpGaD
Masoprocol—ALOX5—Selenium Micronutrient Network—MTHFR—cervical cancer	0.00315	0.0167	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—WNT5A—cervical cancer	0.00309	0.0164	CbGpPWpGaD
Masoprocol—IGF1R—IRS-related events triggered by IGF1R—MTOR—cervical cancer	0.00308	0.0163	CbGpPWpGaD
Masoprocol—IGF1R—SHP2 signaling—EGFR—cervical cancer	0.00304	0.0161	CbGpPWpGaD
Masoprocol—IGF1R—TSH signaling pathway—STAT3—cervical cancer	0.00302	0.016	CbGpPWpGaD
Masoprocol—IGF1R—IGF1R signaling cascade—MTOR—cervical cancer	0.003	0.0159	CbGpPWpGaD
Masoprocol—IGF1R—Apoptosis—CASP3—cervical cancer	0.00296	0.0157	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—TAAR6—cervical cancer	0.00296	0.0157	CbGpPWpGaD
Masoprocol—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	0.00286	0.0151	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—MTOR—cervical cancer	0.0027	0.0143	CbGpPWpGaD
Masoprocol—CYP19A1—FSH signaling pathway—MTOR—cervical cancer	0.00269	0.0143	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—TAAR6—cervical cancer	0.00268	0.0142	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—CASP3—cervical cancer	0.00266	0.0141	CbGpPWpGaD
Masoprocol—IGF1R—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.00249	0.0132	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—EGFR—cervical cancer	0.00231	0.0122	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—WNT2—cervical cancer	0.0021	0.0111	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—EGFR—cervical cancer	0.00203	0.0107	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—AKAP13—cervical cancer	0.00203	0.0107	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.00194	0.0103	CbGpPWpGaD
Masoprocol—IGF1R—Insulin Signaling—MTOR—cervical cancer	0.00192	0.0102	CbGpPWpGaD
Masoprocol—IGF1R—Apoptosis—TP53—cervical cancer	0.0019	0.0101	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—AKAP13—cervical cancer	0.00184	0.00975	CbGpPWpGaD
Masoprocol—LTB4R—Spinal Cord Injury—TP53—cervical cancer	0.0017	0.00902	CbGpPWpGaD
Masoprocol—IGF1R—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.00159	0.00842	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—WNT5A—cervical cancer	0.00159	0.00841	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TAAR6—cervical cancer	0.00159	0.0084	CbGpPWpGaD
Masoprocol—IGF1R—Focal Adhesion—CTNNB1—cervical cancer	0.00149	0.00788	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TAAR6—cervical cancer	0.00135	0.00714	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.00125	0.00665	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—WNT2—cervical cancer	0.00124	0.00656	CbGpPWpGaD
Masoprocol—IGF1R—Focal Adhesion—EGFR—cervical cancer	0.00118	0.00624	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—AKAP13—cervical cancer	0.00109	0.00576	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—WNT2—cervical cancer	0.00105	0.00558	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—WNT5A—cervical cancer	0.000938	0.00497	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—AKAP13—cervical cancer	0.000924	0.0049	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—CA9—cervical cancer	0.000873	0.00462	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000826	0.00437	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—WNT5A—cervical cancer	0.000798	0.00423	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—CA9—cervical cancer	0.000778	0.00412	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—MTOR—cervical cancer	0.000679	0.0036	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—NOTCH2—cervical cancer	0.000659	0.00349	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000625	0.00331	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000602	0.00319	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—NOTCH2—cervical cancer	0.00056	0.00297	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HES1—cervical cancer	0.00054	0.00286	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000477	0.00253	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TERT—cervical cancer	0.000473	0.00251	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HES1—cervical cancer	0.000459	0.00243	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—FGFR3—cervical cancer	0.000434	0.0023	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—NOTCH1—cervical cancer	0.000408	0.00216	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TERT—cervical cancer	0.000402	0.00213	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—CA9—cervical cancer	0.000401	0.00212	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000401	0.00212	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—FGFR3—cervical cancer	0.000369	0.00196	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—EGFR—cervical cancer	0.000363	0.00192	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—MTHFR—cervical cancer	0.000354	0.00188	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—NOTCH1—cervical cancer	0.000347	0.00184	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—MTHFR—cervical cancer	0.000316	0.00167	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—MTOR—cervical cancer	0.000305	0.00162	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—CASP3—cervical cancer	0.000281	0.00149	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—CTNNB1—cervical cancer	0.000271	0.00143	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—MTOR—cervical cancer	0.00026	0.00138	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—CASP3—cervical cancer	0.000239	0.00127	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—STAT3—cervical cancer	0.000236	0.00125	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—CTNNB1—cervical cancer	0.00023	0.00122	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—EGFR—cervical cancer	0.000215	0.00114	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—STAT3—cervical cancer	0.000201	0.00106	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—EGFR—cervical cancer	0.000182	0.000966	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—TP53—cervical cancer	0.00018	0.000954	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—MTHFR—cervical cancer	0.000163	0.000861	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—TP53—cervical cancer	0.000153	0.000811	CbGpPWpGaD
